

I'm not a bot



2019 & 2032Table 77: Europe Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Route of administration 2019 & 2032Table 78: Europe Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Route of administration 2019 & 2032Table 79: Europe Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Indication 2019 & 2032Table 80: Europe Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Indication 2019 & 2032Table 81: Europe Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Country 2019 & 2032Table 82: Europe Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Country 2019 & 2032The projected CAGR is approximately 3.40%.Key companies in the market include Merck And Co, Pfizer, Takeda, Janssen Pharmaceuticals, Eli Lilly, Novartis, Sanofi, AstraZeneca, Bristol Myers Squibb, Novo Nordisk, Boehringer Ingelheim, Astellas.The market segments include Type of Drug, Route of administration, Indication. The market size is estimated to be USD 7.36 Billion as of 2022.Increasing Geriatric Population and Changing Dietary Habits; High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures.Biguamide Segment Occupied the Highest Market Share in the Europe Oral Anti-Diabetic Drugs Market in 2022.Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs; Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs.March 2022: Oramed announced that ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule that has the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed is also developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.The market size is provided in terms of value, measured in Million and volume, measured in K Unit.Yes, the market keyword associated with the report is "Europe Oral Anti-Diabetic Drug Market," which aids in identifying and referencing the specific market segment covered.The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available. To stay informed about further developments, trends, and reports in the Europe Oral Anti-Diabetic Drug Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications. Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufacturers, regional segments, product, and application.Note** In applicable scenarios/Involves using different sources of information in order to increase the validity of a study/These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence.Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.Research AINEWDaily DataServicesDirectly accessible data for 170 industries from 150+ countries and over 1 million facts: Statista+ offers additional, data-driven services, tailored to your specific needs. As your partner for data-driven success, we combine expertise in research, strategy, and marketing communications. Full-service market research and analyticsCustomized market researchData analyticsAd hoc research "askStatista"Research SolutionsStrategy and business building for the data-driven economyBuild strategiesCreate data valueRealize business opportunitiesStrategy ConsultingTransforming data into content marketing and design:Data storytellingCreative assetsDistributionCommunication ServicesStatista R identifies and awards industry leaders, top providers, and exceptional brands throughout exclusive rankings and top lists in collaboration with renowned media brands worldwide. For more details, visit our website.Prices & Access The Europe Oral Anti-Diabetic Drug Market size is estimated at USD 7.36 billion in 2024, and is expected to reach USD 8.70 billion by 2029, growing at a CAGR of 3.40% during the forecast period (2024-2029).The COVID-19 epidemic significantly influenced the European Diabetes Medicines Market. As people with diabetes already have weakened immune systems, COVID-19 causes those immune systems to deteriorate rapidly. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the makers of diabetes pharmaceuticals took special care to ensure that diabetic patients received their meds with the assistance of local governments. On their website, NovoNordisk stated that they "continue to provide our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses.Pharmaceuticals known as diabetic medications were created to stabilize and regulate blood glucose levels in diabetics. Diabetic patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications. The estimated cost per hospital admission for type 2 diabetes patients with good glycemic control during the first wave of COVID-19 in Europe ranged from EUR 25,018 to EUR 57,244 for type 1 diabetes patients with poor glycemic control, reflecting a higher risk of intensive care, ventilator support, and a longer hospital stay. Those without diabetes were expected to pay EUR 16,993. For COVID-19 secondary care, 13.9 billion euros in direct costs were projected to be spent overall in Europe. Hence, diabetes treatment accounted for 23.5% of overall costs.In recent years, diabetes prevalence has increased alarmingly throughout the European continent. Many health issues are related to diabetes. Diabetes patients need to make several adjustments throughout the day to keep their blood glucose levels within normal ranges. For example, they may need to administer more insulin or consume more carbohydrates.As a result of the aforementioned variables, it is projected that the market under study will expand during the course of the investigation.Europe Oral Anti-Diabetic Drug Market TrendsBiguamide Segment Occupied the Highest Market Share in the Europe Oral Anti-Diabetic Drugs Market in 2022The drug metformin is categorized as a biguanide and is used to treat type 2 diabetes. For its "off-label" use in treating persons with disorders like insulin resistance, it is prescribed in 45-50% of all prescriptions and being taken by more than 150 million people annually. The large market share is a result of long-term favorable experience with metformin use, strong evidence of clinical efficacy, safety, high adherence rate, low cost, widespread availability, and cost-effectiveness.In recent years, diabetes prevalence has increased alarmingly throughout the European continent. People with diabetes need to make several adjustments during the day to keep their blood glucose levels within acceptable ranges. Examples include taking oral anti-diabetic medicine or consuming more carbs while keeping an eye on their blood glucose levels. Obesity, a poor diet, and lack of exercise are the main causes of the rise in newly diagnosed Type 1 and Type 2 diabetes cases. Diabetes medicine usage is on the rise, as evidenced by the fast-rising incidence, prevalence, and healthcare costs of diabetes individuals. Oral anti-diabetic medications have been made available globally and are advised for usage when type 2 diabetes therapy needs to be escalated along with lifestyle modification. Due to the wide range of efficacy, safety, and modes of action that oral medicines have, they are frequently the first treatments employed in the treatment of type 2 diabetes. Diabetic patients can minimize their risk of complications and maintain control of their illness with the use of anti-diabetic medications. Throughout the rest of their lives, people with diabetes may need to take anti-diabetic medications to manage their blood sugar levels and prevent hypo and hyperglycemia. Oral anti-diabetic medications have higher acceptance than insulin, which improves adherence to therapy. They also have the advantages of easier control and lower cost.In the Europe Oral Anti-Diabetes Medications Market, Germany holds more than 15% of the market share.Throughout the projected period, Germany is anticipated to dominate the market and post a CAGR of over 3%.One of the astonishing issues facing Germany's healthcare institutions is diabetes, a serious health issue. The adult population of Germany has a very high prevalence of type 1 and type 2 diabetes, as well as a sizable number of individuals who have not yet received a diagnosis. Throughout the coming years, it is anticipated that the prevalence of type 2 diabetes will rise significantly as a result of an aging population and an unhealthy lifestyle. The most important elements in preventing complications in German type 2 diabetes patients are high-quality care, which includes proper monitoring, control of risk factors, and active self-management.The development of novel medications to give diabetic patients more treatment options has been driven by the disease's increasing incidence, prevalence, and progressive nature. More than half of sales in the anti-diabetic market are currently made by non-insulin medications, which are utilized as first-line therapies for type 2 diabetes patients. Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors (DPP-4) are two significant groups that have just entered this market. In order to lower blood sugar levels in persons with type 2 diabetes, oral antidiabetic medications function in a variety of methods. Some increase pancreatic insulin secretion, while others enhance cell insulin sensitivity or stop the liver from producing glucose. Others reduce the rate of glucose absorption following meals.The German Diabetes Center (DDZ) estimates that at least 7.2% of the population in Germany presently has diabetes, and that number will rise dramatically over the next 20 years. According to German legislation, public insurance plans must cap out-of-pocket medical expenses and provide coverage for all medically essential procedures, including oral Anti-Diabetes Market. One of the developed nations with cutting-edge medical facilities in Germany. The market is further driven by the strict regulation of pricing and reimbursement policies. Some of the potential prospects for the companies in the German diabetes medications market include the introduction of several new products, expanding international research collaborations for technological advancement, and raising public awareness of diabetes.Europe Oral Anti-Diabetic Drug Industry OverviewThe Europe oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs. Additional BenefitsThe market estimate (ME) sheet in Excel format3 months of analyst supportThis product will be delivered within 2 business days. 1.1 Study Assumptions and Market Definition1.2 Scope of the Study2. RESEARCH METHODOLOGY3. EXECUTIVE SUMMARY4. MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.3 Market Restraints 4.4 Porter's Five Forces Analysis 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Consumers 4.4.3 Threat of New Entrants 4.4.4 Threat of Substitute Products and Services 4.4.5 Intensity of Competitive Rivalry5. Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)5.1.1 Biguamides 5.1.1.1 Metformin5.1.1.2 Alpha-Glucosidase Inhibitors5.1.1.1.1 Invokana (Canagliflozin)5.1.1.1.2 Farxiga/Forxiga (Dapagliflozin)5.1.1.1.3 Saxagliptin (Saxagliptin)5.1.1.1.4 Galvus (Vildagliptin)5.1.1.1.5 Vildagliptin5.1.1.1.6 Galvus (Vildagliptin)5.1.1.1.7 Meglitinides5.1.1.1.8 Novartis (Nesina)5.1.1.1.9 Galvus (Vildagliptin)5.1.1.1.10 Galvus (Vildagliptin)5.1.1.1.11 Galvus (Vildagliptin)5.1.1.1.12 Galvus (Vildagliptin)5.1.1.1.13 Galvus (Vildagliptin)5.1.1.1.14 Galvus (Vildagliptin)5.1.1.1.15 Galvus (Vildagliptin)5.1.1.1.16 Galvus (Vildagliptin)5.1.1.1.17 Galvus (Vildagliptin)5.1.1.1.18 Galvus (Vildagliptin)5.1.1.1.19 Galvus (Vildagliptin)5.1.1.1.20 Galvus (Vildagliptin)5.1.1.1.21 Galvus (Vildagliptin)5.1.1.1.22 Galvus (Vildagliptin)5.1.1.1.23 Galvus (Vildagliptin)5.1.1.1.24 Galvus (Vildagliptin)5.1.1.1.25 Galvus (Vildagliptin)5.1.1.1.26 Galvus (Vildagliptin)5.1.1.1.27 Galvus (Vildagliptin)5.1.1.1.28 Galvus (Vildagliptin)5.1.1.1.29 Galvus (Vildagliptin)5.1.1.1.30 Galvus (Vildagliptin)5.1.1.1.31 Galvus (Vildagliptin)5.1.1.1.32 Galvus (Vildagliptin)5.1.1.1.33 Galvus (Vildagliptin)5.1.1.1.34 Galvus (Vildagliptin)5.1.1.1.35 Galvus (Vildagliptin)5.1.1.1.36 Galvus (Vildagliptin)5.1.1.1.37 Galvus (Vildagliptin)5.1.1.1.38 Galvus (Vildagliptin)5.1.1.1.39 Galvus (Vildagliptin)5.1.1.1.40 Galvus (Vildagliptin)5.1.1.1.41 Galvus (Vildagliptin)5.1.1.1.42 Galvus (Vildagliptin)5.1.1.1.43 Galvus (Vildagliptin)5.1.1.1.44 Galvus (Vildagliptin)5.1.1.1.45 Galvus (Vildagliptin)5.1.1.1.46 Galvus (Vildagliptin)5.1.1.1.47 Galvus (Vildagliptin)5.1.1.1.48 Galvus (Vildagliptin)5.1.1.1.49 Galvus (Vildagliptin)5.1.1.1.50 Galvus (Vildagliptin)5.1.1.1.51 Galvus (Vildagliptin)5.1.1.1.52 Galvus (Vildagliptin)5.1.1.1.53 Galvus (Vildagliptin)5.1.1.1.54 Galvus (Vildagliptin)5.1.1.1.55 Galvus (Vildagliptin)5.1.1.1.56 Galvus (Vildagliptin)5.1.1.1.57 Galvus (Vildagliptin)5.1.1.1.58 Galvus (Vildagliptin)5.1.1.1.59 Galvus (Vildagliptin)5.1.1.1.60 Galvus (Vildagliptin)5.1.1.1.61 Galvus (Vildagliptin)5.1.1.1.62 Galvus (Vildagliptin)5.1.1.1.63 Galvus (Vildagliptin)5.1.1.1.64 Galvus (Vildagliptin)5.1.1.1.65 Galvus (Vildagliptin)5.1.1.1.66 Galvus (Vildagliptin)5.1.1.1.67 Galvus (Vildagliptin)5.1.1.1.68 Galvus (Vildagliptin)5.1.1.1.69 Galvus (Vildagliptin)5.1.1.1.70 Galvus (Vildagliptin)5.1.1.1.71 Galvus (Vildagliptin)5.1.1.1.72 Galvus (Vildagliptin)5.1.1.1.73 Galvus (Vildagliptin)5.1.1.1.74 Galvus (Vildagliptin)5.1.1.1.75 Galvus (Vildagliptin)5.1.1.1.76 Galvus (Vildagliptin)5.1.1.1.77 Galvus (Vildagliptin)5.1.1.1.78 Galvus (Vildagliptin)5.1.1.1.79 Galvus (Vildagliptin)5.1.1.1.80 Galvus (Vildagliptin)5.1.1.1.81 Galvus (Vildagliptin)5.1.1.1.82 Galvus (Vildagliptin)5.1.1.1.83 Galvus (Vildagliptin)5.1.1.1.84 Galvus (Vildagliptin)5.1.1.1.85 Galvus (Vildagliptin)5.1.1.1.86 Galvus (Vildagliptin)5.1.1.1.87 Galvus (Vildagliptin)5.1.1.1.88 Galvus (Vildagliptin)5.1.1.1.89 Galvus (Vildagliptin)5.1.1.1.90 Galvus (Vildagliptin)5.1.1.1.91 Galvus (Vildagliptin)5.1.1.1.92 Galvus (Vildagliptin)5.1.1.1.93 Galvus (Vildagliptin)5.1.1.1.94 Galvus (Vildagliptin)5.1.1.1.95 Galvus (Vildagliptin)5.1.1.1.96 Galvus (Vildagliptin)5.1.1.1.97 Galvus (Vildagliptin)5.1.1.1.98 Galvus (Vildagliptin)5.1.1.1.99 Galvus (Vildagliptin)5.1.1.1.100 Galvus (Vildagliptin)5.1.1.1.101 Galvus (Vildagliptin)5.1.1.1.102 Galvus (Vildagliptin)5.1.1.1.103 Galvus (Vildagliptin)5.1.1.1.104 Galvus (Vildagliptin)5.1.1.1.105 Galvus (Vildagliptin)5.1.1.1.106 Galvus (Vildagliptin)5.1.1.1.107 Galvus (Vildagliptin)5.1.1.1.108 Galvus (Vildagliptin)5.1.1.1.109 Galvus (Vildagliptin)5.1.1.1.110 Galvus (Vildagliptin)5.1.1.1.111 Galvus (Vildagliptin)5.1.1.1.112 Galvus (Vildagliptin)5.1.1.1.113 Galvus (Vildagliptin)5.1.1.1.114 Galvus (Vildagliptin)5.1.1.1.115 Galvus (Vildagliptin)5.1.1.1.116 Galvus (Vildagliptin)5.1.1.1.117 Galvus (Vildagliptin)5.1.1.1.118 Galvus (Vildagliptin)5.1.1.1.119 Galvus (Vildagliptin)5.1.1.1.120 Galvus (Vildagliptin)5.1.1.1.121 Galvus (Vildagliptin)5.1.1.1.122 Galvus (Vildagliptin)5.1.1.1.123 Galvus (Vildagliptin)5.1.1.1.124 Galvus (Vildagliptin)5.1.1.1.125 Galvus (Vildagliptin)5.1.1.1.126 Galvus (Vildagliptin)5.1.1.1.127 Galvus (Vildagliptin)5.1.1.1.128 Galvus (Vildagliptin)5.1.1.1.129 Galvus (Vildagliptin)5.1.1.1.130 Galvus (Vildagliptin)5.1.1.1.131 Galvus (Vildagliptin)5.1.1.1.132 Galvus (Vildagliptin)5.1.1.1.133 Galvus (Vildagliptin)5.1.1.1.134 Galvus (Vildagliptin)5.1.1.1.135 Galvus (Vildagliptin)5.1.1.1.136 Galvus (Vildagliptin)5.1.1.1.137 Galvus (Vildagliptin)5.1.1.1.138 Galvus (Vildagliptin)5.1.1.1.139 Galvus (Vildagliptin)5.1.1.1.140 Galvus (Vildagliptin)5.1.1.1.141 Galvus (Vildagliptin)5.1.1.1.142 Galvus (Vildagliptin)5.1.1.1.143 Galvus (Vildagliptin)5.1.1.1.144 Galvus (Vildagliptin)5.1.1.1.145 Galvus (Vildagliptin)5.1.1.1.146 Galvus (Vildagliptin)5.1.1.1.147 Galvus (Vildagliptin)5.1.1.1.148 Galvus (Vildagliptin)5.1.1.1.149 Galvus (Vildagliptin)5.1.1.1.150 Galvus (Vildagliptin)5.1.1.1.151 Galvus (Vildagliptin)5.1.1.1.152 Galvus (Vildagliptin)5.1.1.1.153 Galvus (Vildagliptin)5.1.1.1.154 Galvus (Vildagliptin)5.1.1.1.155 Galvus (Vildagliptin)5.1.1.1.156 Galvus (Vildagliptin)5.1.1.1.157 Galvus (Vildagliptin)5.1.1.1.158 Galvus (Vildagliptin)5.1.1.1.159 Galvus (Vildagliptin)5.1.1.1.160 Galvus (Vildagliptin)5.1.1.1.161 Galvus (Vildagliptin)5.1.1.1.162 Galvus (Vildagliptin)5.1.1.1.163 Galvus (Vildagliptin)5.1.1.1.164 Galvus (Vildagliptin)5.1.1.1.165 Galvus (Vildagliptin)5.1.1.1.166 Galvus (Vildagliptin)5.1.1.1.167 Galvus (Vildagliptin)5.1.1.1.168 Galvus (Vildagliptin)5.1.1.1.169 Galvus (Vildagliptin)5.1.1.1.170 Galvus (Vildagliptin)5.1.1.1.171 Galvus (Vildagliptin)5.1.1.1.172 Galvus (Vildagliptin)5.1.1.1.173 Galvus (Vildagliptin)5.1.1.1.174 Galvus (Vildagliptin)5.1.1.1.175 Galvus (Vildagliptin)5.1.1.1.176 Galvus (Vildagliptin)5.1.1.1.177 Galvus (Vildagliptin)5.1.1.1.178 Galvus (Vildagliptin)5.1.1.1.179 Galvus (Vildagliptin)5.1.1.1.180 Galvus (Vildagliptin)5.1.1.1.181 Galvus (Vildagliptin)5.1.1.1.182 Galvus (Vildagliptin)5.1.1.1.183 Galvus (Vildagliptin)5.1.1.1.184 Galvus (Vildagliptin)5.1.1.1.185 Galvus (Vildagliptin)5.1.1.1.186 Galvus (Vildagliptin)5.1.1.1.187 Galvus (Vildagliptin)5.1.1.1.188 Galvus (Vildagliptin)5.1.1.1.189 Galvus (Vildagliptin)5.1.1.1.190 Galvus (Vildagliptin)5.1.1.1.191 Galvus (Vildagliptin)5.1.1.1.192 Galvus (Vildagliptin)5.1.1.1.193 Galvus (Vildagliptin)5.1.1.1.194 Galvus (Vildagliptin)5.1.1.1.195 Galvus (Vildagliptin)5.1.1.1.196 Galvus (Vildagliptin)5.1.1.1.197 Galvus (Vildagliptin)5.1.1.1.198 Galvus (Vildagliptin)5.1.1.1.199 Galvus (Vildagliptin)5.1.1.1.200 Galvus (Vildagliptin)5.1.1.1.201 Galvus (Vildagliptin)5.1.1.1.202 Galvus (Vildagliptin)5.1.1.1.203 Galvus (Vildagliptin)5.1.1.1.204 Galvus (Vildagliptin)5.1.1.1.205 Galvus (Vildagliptin)5.1.1.1.206 Galvus (Vildagliptin)5.1.1.1.207 Galvus (Vildagliptin)5.1.1.1.208 Galvus (Vildagliptin)5.1.1.1.209 Galvus (Vildagliptin)5.1.1.1.210 Galvus (Vildagliptin)5.1.1.1.211 Galvus (Vildagliptin)5.1.1.1.212 Galvus (Vildagliptin)5.1.1.1.213 Galvus (Vildagliptin)5.1.1.1.214 Galvus (Vildagliptin)5.1.1.1.215 Galvus (Vildagliptin)5.1.1.1.216 Galvus (Vildagliptin)5.1.1.1.217 Galvus (Vildagliptin)5.1.1.1.218 Galvus (Vildagliptin)5.1.1.1.219 Galvus (Vildagliptin)5.1.1.1.220 Galvus (Vildagliptin)5.1.1.1.221 Galvus (Vildagliptin)5.1.1.1.222 Galvus (Vildagliptin)5.1.1.1.223 Galvus (Vildagliptin)5.1.1.1.224 Galvus (Vildagliptin)5.1.1.1.225 Galvus (Vildagliptin)5.1.1.1.226 Galvus (Vildagliptin)5.1.1.1.227 Galvus (Vildagliptin)5.1.1.1.228 Galvus (Vildagliptin)5.1.1.1.229 Galvus (Vildagliptin)5.1.1.1.230 Galvus (Vildagliptin)5.1.1.1.231 Galvus (Vildagliptin)5.1.1.1.232 Galvus (Vildagliptin)5.1.1.1.233 Galvus (Vildagliptin)5.1.1.1.234 Galvus (Vildagliptin)5.1.1.1.235 Galvus (Vildagliptin)5.1.1.1.236 Galvus (Vildagliptin)5.1.1.1.237 Galvus (Vildagliptin)5.1.1.1.238 Galvus (Vildagliptin)5.1.1.1.239 Galvus (Vildagliptin)5.1.1.1.240 Galvus (Vildagliptin)5.1.1.1.241 Galvus (Vildagliptin)5.1.1.1.242 Galvus (Vildagliptin)5.1.1.1.243 Galvus (Vildagliptin)5.1.1.1.244 Galvus (Vildagliptin)5.1.1.1.245 Galvus (Vildagliptin)5.1.1.1.246 Galvus (Vildagliptin)5.1.1.1.247 Galvus (Vildagliptin)5.1.1.1.248 Galvus (Vildagliptin)5.1.1.1.249 Galvus (Vildagliptin)5.1.1.1.250 Galvus (Vildagliptin)5.1.1.1.251 Galvus (Vildagliptin)5.1.1.1.252 Galvus (Vildagliptin)5.1.1.1.253 Galvus (Vildagliptin)5.1.1.1.254 Galvus (Vildagliptin)5.1.1.1.255 Galvus (Vildagliptin)5.1.1.1.256 Galvus (Vildagliptin)5.1.1.1.257 Galvus (Vildagliptin)5.1.1.1.258 Galvus (Vildagliptin)5.1.1.1.259 Galvus (Vildagliptin)5.1.1.1.260 Galvus (Vildagliptin)5.1.1.1.261 Galvus (Vildagliptin)5.1.1.1.262 Galvus (Vildagliptin)5.1.1.1.263 Galvus (Vildagliptin)5.1.1.1.264 Galvus (Vildagliptin)5.1.1.1.265 Galvus (Vildagliptin)5.1.1.1.266 Galvus (Vildagliptin)5.1.1.1.267 Galvus (Vildagliptin)5.1.1.1.268 Galvus (Vildagliptin)5.1.1.1.269 Galvus (Vildagliptin)5.1.1.1.270 Galvus (Vildagliptin)5.1.1.1.271 Galvus (Vildagliptin)5.1.1.1.272 Galvus (Vildagliptin)5.1.1.1.273 Galvus (Vildagliptin)5.1.1.1.274 Galvus (Vildagliptin)5.1.1.1.275 Galvus (Vildagliptin)5.1.1.1.276 Galvus (Vildagliptin)5.1.1.1.277 Galvus (Vildagliptin)5.1.1.1.278 Galvus (Vildagliptin)5.1.1.1.279 Galvus (Vildagliptin)5.1.1.1.280 Galvus (Vildagliptin)5.1.1.1.281 Galvus (Vildagliptin)5.1.1.1.282 Galvus (Vildagliptin)5.1.1.1.283 Galvus (Vildagliptin)5.1.1.1.284 Galvus (Vildagliptin)5.1.1.1.285 Galvus (Vildagliptin)5.1.1.1.286 Galvus (Vildagliptin)5.1.1.1.287 Galvus (Vildagliptin)5.1.1.1.288 Galvus (Vildagliptin)5.1.1.1.289 Galvus (Vildagliptin)5.1.1.1.290 Galvus (Vildagliptin)5.1.1.1.291 Galvus (Vildagliptin)5.1.1.1.292 Galvus (Vildagliptin)5.1.1.1.293 Galvus (Vildagliptin)5.1.1.1.294 Galvus (Vildagliptin)5.1.1.1.295 Galvus (Vildagliptin)5.1.1.1.296 Galvus (Vildagliptin)5.1.1.1.297 Galvus (Vildagliptin)5.1.1.1.298 Galvus (Vildagliptin)5.1.1.1.299 Galvus (Vildagliptin)5.1.1.1.300 Galvus (Vildagliptin)5.1.1.1.301 Galvus (Vildagliptin)5.1.1.1.302 Galvus (Vildagliptin)5.1.1.1.303 Galvus (Vildagliptin)5.1.1.1.304 Galvus (Vildagliptin)5.1.1.1.305 Galvus (Vildagliptin)5.1.1.1.306 Galvus (Vildagliptin)5.1.1.1.307 Galvus (Vildagliptin)5.1.1.1.308 Galvus (Vildagliptin)5.1.1.1.309 Galvus (Vildagliptin)5.1.1.1.310 Galvus (Vildagliptin)5.1.1.1.311 Galvus (Vildagliptin)5.1.1.1.312 Galvus (Vildagliptin)5.1.1.1.313 Galvus (Vildagliptin)5.1.1.1.314 Galvus (Vildagliptin)5.1.1.1.315 Galvus (Vildagliptin)5.1.1.1.316 Galvus (Vildagliptin)5.1.1.1.317 Galvus (Vildagliptin)5.1.1.1.318 Galvus (Vildagliptin)5.1.1.1.319 Galvus (Vildagliptin)5.1.1.1.320 Galvus (Vildagliptin)5.1.1.1.321 Galvus (Vildagliptin)5.1.1.1.322 Galvus (Vildagliptin)5.1.1.1.323 Galvus (Vildagliptin)5.1.1.1.324 Galvus (Vildagliptin)5.1.1.1.325 Galvus (Vildagliptin)5.1.1.1.326 Galvus (Vildagliptin)5.1.1.1.327 Galvus (Vildagliptin)5.1.1.1.328 Galvus (Vildagliptin)5.1.1.1.329 Galvus (Vildagliptin)5.1.1.1.330 Galvus (Vildagliptin)5.1.1.1.331 Galvus (Vildagliptin)5.1.1.1.332 Galvus (Vildagliptin)5.1.1.1.333 Galvus (Vildagliptin)5.1.1.1.334 Galvus (Vildagliptin)5.1.1.1.335 Galvus (Vildagliptin)5.1.1.1.336 Galvus (Vildagliptin)5.1.1.1.337 Galvus (Vildagliptin)5.1.1.1.338 Galvus (Vildagliptin)5.1.1.1.339 Galvus (Vildagliptin)5.1.1.1.340 Galvus (Vildagliptin)5.1.1.1.341 Galvus (Vildagliptin)5.1.1.1.342 Galvus (Vildagliptin)5.1.1.1.343 Galvus (Vildagliptin)5.1.1.1.344 Galvus (Vildagliptin)5.1.1.1.345 Galvus (Vildagliptin)5.1.1.1.346 Galvus (Vildagliptin)5.1.1.1.347 Galvus (Vildagliptin)5.1.1.1.348 Galvus (Vildagliptin)5.1.1.1.349 Galvus (Vildagliptin)5.1.1.1.350 Galvus (Vildagliptin)5.1.1.1.351 Galvus (Vildagliptin)5.1.1.1.352 Galvus (Vildagliptin)5.1.1.1.353 Galvus (Vildagliptin)5.1.1.1.354 Galvus (Vildagliptin)5.1.1.1.355 Galvus (Vildagliptin)5.1.1.1.356 Galvus (Vildagliptin)5.1.1.1.357 Galvus (Vildagliptin)5.1.1.1.358 Galvus (Vildagliptin)5.1.1.1.359 Galvus (Vildagliptin)5.1.1.1.360 Galvus (Vildagliptin)5.1.1.1.361 Galvus (Vildagliptin)5.1.1.1.362 Galvus (Vildagliptin)5.1.1.1.363 Galvus (Vildagliptin)5.1.1.1.364 Galvus (Vildagliptin)5.1.1.1.365 Galvus (Vildagliptin)5.1.1.1.366 Galvus (Vildagliptin)5.1.1.1.367 Galvus (Vildagliptin)5.1.1.1.368 Galvus (Vildagliptin)5.1.1.1.369 Galvus (Vildagliptin)5.1.1.1.370 Galvus (Vildagliptin)5.1.1.1.371 Galvus (Vildagliptin)5.1.1.1.372 Galvus (Vildagliptin)5.1.1.1.373 Galvus (Vildagliptin)5.1.1.1.374 Galvus (Vildagliptin)5.1.1.1.375 Galvus (Vildagliptin)5.1.1.1.376 Galvus (Vildagliptin)5.1.1.1.377 Galvus (Vildagliptin)5.1.1.1.378 Galvus (Vildagliptin)5.1.1.1.379 Galvus (Vildagliptin)5.1.1.1.380 Galvus (Vildagliptin)5.1.1.1.381 Galvus (Vildagliptin)5.1.1.1.382 Galvus (Vildagliptin)5.1.1.1.383 Galvus (Vildagliptin)5.1.1.1.384 Galvus (Vildagliptin)5.1.1.1.385 Galvus (Vildagliptin)5.1.1.1.386 Galvus (Vildagliptin)5.1.1.1.387 Galvus (Vildagliptin)5.1.1.1.388 Galvus (Vildagliptin)5.1.1.1.389 Galvus (Vildagliptin)5.1.1.1.390 Galvus (Vildagliptin)5.1.1.1.391 Galvus (Vildagliptin)5.1.1.1.392 Galvus (Vildagliptin)5.1.1.1.393 Galvus (Vildagliptin)5.1.1.1.394 Galvus (Vildagliptin)5.1.1.1.395 Galvus (Vildagliptin)5.1.1.1.396 Galvus (Vildagliptin)5.1.1.1.397 Galvus (Vildagliptin)5.1.1.1.398 Galvus (Vildagliptin)5.1.1.1.399 Galvus (Vildagliptin)5.1.1.1.400 Galvus (Vildagliptin)5.1.1.1.401 Galvus (Vildagliptin)5.1.1.1.402 Galvus (Vildagliptin)5.1.1.1.403 Galvus (Vildagliptin)5.1.1.1.404 Galvus (Vildagliptin)5.1.1.1.405 Galvus (Vildagliptin)5.1.1.1.406 Galvus (Vildagliptin)5.1.1.1.407 Galvus (Vildagliptin)5.1.1.1.408 Galvus (Vildagliptin)5.1.1.1.409 Galvus (Vildagliptin)5.1.1.1.410 Galvus (Vildagliptin)5.1.1.1.411 Galvus (Vildagliptin)5.1.1.1.412 Galvus (Vildagliptin)5.1.1.1.413 Galvus (Vildagliptin)5.1.1.1.414 Galvus (Vildagliptin)5.1.1.1.415 Galvus (Vildagliptin)5.1.1.1.416 Galvus (Vildagliptin)5.1.1.1.417 Galvus (Vildagliptin)5.1.1.1.418 Galvus (Vildagliptin)5.1.1.1.419 Galvus (Vildagliptin)5.1.1.1.420 Galvus (Vildagliptin)5.1.1.1.421 Galvus (Vildagliptin)5.1.1.1.422 Galvus (Vildagliptin)5.1.1.1.423 Galvus (Vildagliptin)5.1.1.1.424 Galvus (Vildagliptin)5.1.1.1.425 Galvus (Vildagliptin)5.1.1.1.426 Galvus (Vildagliptin)5.1.1.1.427 Galvus (Vildagliptin)5.1.1.1.428 Galvus (Vildagliptin)5.1.1.1.429 Galvus (Vildagliptin)5.1.1.1.430 Galvus (Vildagliptin)5.1.1.1.431 Galvus (Vildagliptin)5.1.1.1.432 Galvus (Vildagliptin)5.1.1.1.433 Galvus (Vildagliptin)5.1.1.1.434 Galvus (Vildagliptin)5.1.1.1.435 Galvus (Vildagliptin)5.1.1.1.436 Galvus (Vildagliptin)5.1.1.1.437 Galvus (Vildagliptin)5.1.1.1.438 Galvus (Vildagliptin)5.1.1.1.439 Galvus (Vildagliptin)5.1.1.1.440 Galvus (Vildagliptin)5.1.1.1.441 Galvus (Vildagliptin)5.1.1.1.442 Galvus (Vildagliptin)5.1.1.1.443 Galvus (Vildagliptin)5.1.1.1.444 Galvus (Vildagliptin)5.1.1.1.445 Galvus (Vildagliptin)5.1.1.1.446 Galvus (Vildagliptin)5.1.1.1.447 Galvus (Vildagliptin)5.1.1.1.448 Galvus (Vildagliptin)5.1.1.1.449 Galvus (Vildagliptin)5.1.1.1.450 Galvus (Vildagliptin)5.1.1.1.451 Galvus (Vildagliptin)5.1.1.1.452 Galvus (Vildagliptin)5.1.1.1.453 Galvus (Vildagliptin)5.1.1.1.454 Galvus (Vildagliptin)5.1.1.1.455 Galvus (Vildagliptin)5.1.1.1.456 Galvus (Vildagliptin)5.1.1.1.457 Galvus (Vildagliptin)5.1.1.1.458 Galvus (Vildagliptin)5.1.1.1.459 Galvus (Vildagliptin)5.1.1.1.460 Galvus (Vildagliptin)5.1.1.1.461 Galvus (Vildagliptin)5.1.1.1.462 Galvus (Vildagliptin)5.1.1.1.463 Galvus (Vildagliptin)5.1.1.1.464 Galvus (Vildagliptin)5.1.1.1.465 Galvus (Vildagliptin)5.1.1.1.466 Galvus (Vildagliptin)5.1.1.1.467 Galvus (Vildagliptin)5.1.1.1.468 Galvus (Vildagliptin)5.1.1.1.469 Galvus (Vildagliptin)5.1.1.1.470 Galvus (Vildagliptin)5.1.1.1.471 Galvus (Vildagliptin)5.1.1.1.472 Galvus (Vildagliptin)5.1.1.1.473 Galvus (Vildagliptin)5.1.1.1.474 Galvus (Vildagliptin)5.1.1.1.475 Galvus (Vildagliptin)5.1.1.1.476 Galvus (Vildagliptin)5.1.1.1.477 Galvus (Vildagliptin)5.1.1.1.478 Galvus (Vildagliptin)5.1.1.1.479 Galvus (Vildagliptin)5.1.1.1.480 Galvus (Vildagliptin)5.1.1.1.481 Galvus (Vildagliptin)5.1.1.1.482 Galvus (Vildagliptin)5.1.1.1.483 Galvus (Vildagliptin)5.1.1.1.484 Galvus (Vildagliptin)5.1.1.1.485 Galvus (Vildagliptin)5.1.1.1.486 Galvus (Vildagliptin)5.1.1.1.487 Galvus (Vildagliptin)5.1.1.1.488 Galvus (Vildagliptin)5.1.1.1.48